International Journal of Clinical Research

Objective To analyze the effect of the preparation and application of hydrogel dressing loaded with miR-27b inhibitor on diabetic foot. Methods The study was carried out from January 2021 to December 2023. Thirty diabetic foot rats were selected. All experimental subjects were intraperitoneally injected with 55 mg/kg streptozotocin every day for one week to establish a model of diabetic foot ulcer. A 4×4 mm wound was made on the hind feet of diabetic rats. The 30 diabetic foot rats were divided into three groups: blank control group, high-glucose hydrogel group without miR-27b inhibitor (abbreviated as: no miR-27b group), and high-glucose hydrogel group with miR-27b inhibitor (abbreviated as: rich in miR-27b group), with 10 rats in each group. At the 2nd, 4th and 8th week after treatment, samples were collected from the corresponding wounds to observe the contents of inflammatory factors IL-1β, TNF-α, IL-10 and PMNs in the cells of each group, the growth of granulation tissue in the wound and the expression of PI3K/AKT pathway-related proteins in the cells of each group. Results The contents of inflammatory factors IL-1β, TNF-α and IL-10 in the cells of the miR-27b-rich group at 2, 4 and 8 weeks were lower than those in the blank control group and the group without miR-27b, and the granulation tissue growth rate and the expression of PI3K/AKT pathway-related proteins in the cells of each group were better than those in the blank control group and the group without miR-27b, and the differences were statistically significant (P<0.05). Conclusion The application of hydrogel dressing loaded with miR-27b inhibitor on diabetic foot wounds can reduce inflammatory factors, regulate PI3K/AKT pathway-related proteins, promote the maturation of granulation tissue in the wound, and promote the transformation from connective tissue to scar tissue.

Hydrogel dressing loaded with miR-27b inhibitor; Diabetic foot; PI3K/AKT pathway-related proteins; MicroRNA-27b